Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: RG Please...

I recommended your post. I wish to make the following 2 comments:

1. "PTSC is treading water." I disagree with this statemnt. PTSC has about $19 million cash on hand (I may be wrong on the amount, someone will no doubt correct me, please) Looking over the investing landscape I would say that is a strong positon for a small company in today's business environment. There are so many examples of companies burnig through cash and looking just to survice. PTSC has a growing business in the Crossflow/Iameter venture with a relatively small revenue but growing stream. The MMP licensing potential is still ther and seems stronger now (German validation) while awaiting the glacier like USPTO to finish its reexam. I fully expect USPTO to recertify MMP.

2. TPL and PTSC each receive 50% in the licensing fees with Alliacence handling the negotiating with potential licensees. TPL and PTSC also share in the costs (from Alliacense) equally. I am mystified by those who claim TPL is benefiting from the MMP licensing at the expense of PTSC.

Share
New Message
Please login to post a reply